Pneumologie 2019; 73(S 01)
DOI: 10.1055/s-0039-1678138
Freie Vorträge (FV DGP 8) – Sektion Pneumologische Onkologie
Lungenkarzinom
Georg Thieme Verlag KG Stuttgart · New York

Real World Molecular Testing in Patients with EGFR-Mutation-Positive locally advanced or advanced NSCLC in routine practice in Germany – Interim results of the clinical registry PANORAMA (NCT02777658)

C Schumann
1   Clinic for Pneumology, Thoracic Oncology, Sleep- and Respiratory Critical Care, Kempten-Oberallgaeu Hospitals
,
R Büttner
2   Institute for Pathology, University Hospital of Cologne
,
KM Deppermann
3   Lung Center – Department of Pneumology, Sana Kliniken Düsseldorf
,
N Reinmuth
4   Department of Thoracic Oncology, Asklepios Fachklinik München-Gauting, Member of the German Center for Lung Research (Dzl)
,
W Schütte
5   Department of Internal Medicine II, Martha-Maria Krankenhaus Halle-Dölau gGmbH
,
M Thomas
6   Internistische Onkologie der Thoraxtumoren, Thoraxklinik Im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (Tlrc-H), Member of the German Center for Lung Research
,
M Wroblewski
7   Astrazeneca GmbH
,
F Griesinger
8   Department of Hematology and Oncology, Pius Hospital Oldenburg
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. Februar 2019 (online)

Auch verfügbar auf
 
 

    Introduction Epidermal Growth Factor Receptor mutations (EGFRm) are among the most common in patients (pts) with non-small cell lung cancer (NSCLC) and can be targeted with EGFR tyrosine kinase inhibitors (TKI). Approx. 50% of the pts will acquire resistance by the T790M mutation (T790M). Osimertinib is a 3rd generation EGFR-TKI and standard of care (SoC) for pts who developed the acquired resistance by T790M during prior EGFR-TKI treatments, while other strategies, such as chemotherapy (CT) is used in T790M negative pts. The need for re-biopsy and molecular testing to determine T790M status and the resultant shift from a CT-based regimen to oral targeted therapy will further impact the current SoC and management practices.

    Methods PANORAMA is a prospective, clinical registry for pts with EGFRm locally advanced or metastatic NSCLC, who progressed after prior TKI therapy (cohort 1) or pts diagnosed with de novo EGFR T790M (cohort 2). Beside others, data on pts characteristics, molecular testing, treatment patterns, associated clinical outcomes and pts health-related quality of life (EORTC QLQ-C30, LC13) are collected. Started in May 2016, 73 sites have been recruiting 101 pts (April 2018). Pts will be followed until death, loss to follow-up, withdrawal of consent or study end date (Q2/2020). The 1st interim analysis (cut-off date: 1-April-2018) was conducted for the cohort 1. Data were analyzed by descriptive statistics.

    Results The 1st interim analysis will provide data of 93 evaluable pts: At diagnosis median age was 67.8 yrs (min-max 43.8 – 83.8 yrs), 33% of pts were male and 60% were diagnosed with NSCLC Stage IV. As per inclusion criteria, all pts had been tested for EGFRm, 73 pts (78%) had been tested at the time of diagnosis, the remaining pts at later time points. After progression on/after TKI 50 pts (54%) were tested again (no testing in 14 pts, currently incomplete/missing data: 29 pts). Further results including data on molecular testing and treatment strategies after progression on/after TKI therapy in routine practice in Germany will be presented.

    Conclusions The results from PANORAMA will help to understand evolving Real World pts management, treatment patterns and associated outcomes among pts with EGFRm locally advanced or metastatic NSCLC who have progressed on/after EGFR-TKI therapy.

    Sponsor: AstraZeneca


    #